The solution is called anti-coronavirus hyperimmune intravenous immunoglobulin, or hIVIG. It’s a more-concentrated convalescent plasma that contains several times the amount of antibodies than are typically found in the plasma of people who have recovered from COVID-19, the NIH said.
Anti-coronavirus hIVIG may be a more sustainable treatment for COVID-19 patients, as convalescent plasma must be used within 24 hours, whereas anti-coronavirus hIVIG can be stored for as long as three years, The Wall Street Journal reported.
The trial will test whether giving people the anti-coronavirus hIVIG at the onset of symptoms, before the body makes a protective immune response on its own, could reduce the risk of a more serious case of COVID-19 or death.
The phase 3 study is taking place in hospitalized adults in the U.S., Mexico and 16 other countries. It will enroll 500 adults who have had COVID-19 symptoms for 13 days or fewer and who don’t have life-threatening organ dysfunction or organ failure.
Four companies are collaborating to provide the anti-coronavirus hIVIG for the trial: Emergent Biosolutions, Grifols, CSL Behring and Takeda Pharmaceuticals.
More articles on pharmacy:
7 key uncertainties surrounding the COVID-19 vaccine race
Mallinckrodt files for Chapter 11 bankruptcy
Operation Warp Speed czar: Vaccine approval likely to be sought around Thanksgiving
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.